Literature DB >> 29462364

Bioavailability and Pharmacokinetics of Oral Cocaine in Humans.

Marion A Coe1,2, Rebecca A Jufer Phipps3,4, Edward J Cone3,5, Sharon L Walsh1,2,6,2.   

Abstract

The pharmacokinetic profile of oral cocaine has not been fully characterized and prospective data on oral bioavailability are limited. A within-subject study was performed to characterize the bioavailability and pharmacokinetics of oral cocaine. Fourteen healthy inpatient participants (six males) with current histories of cocaine use were administered two oral doses (100 and 200 mg) and one intravenous (IV) dose (40 mg) of cocaine during three separate dosing sessions. Plasma samples were collected for up to 24 h after dosing and analyzed for cocaine and metabolites by gas chromatography-mass spectrometry. Pharmacokinetic parameters were calculated by non-compartmental analysis, and a two-factor model was used to assess for dose and sex differences. The mean ± SEM oral cocaine bioavailability was 0.32 ± 0.04 after 100 and 0.45 ± 0.06 after 200 mg oral cocaine. Volume of distribution (Vd) and clearance (CL) were both greatest after 100 mg oral (Vd = 4.2 L/kg; CL = 116.2 mL/[min kg]) compared to 200 mg oral (Vd = 2.9 L/kg; CL = 87.5 mL/[min kg]) and 40 mg IV (Vd = 1.3 L/kg; CL = 32.7 mL/[min kg]). Oral cocaine area-under-thecurve (AUC) and peak concentration increased in a dose-related manner. AUC metabolite-to-parent ratios of benzoylecgonine and ecgonine methyl ester were significantly higher after oral compared to IV administration and highest after the lower oral dose. In addition, minor metabolites were detected in higher concentrations after oral compared to IV cocaine. Oral cocaine produced a pharmacokinetic profile different from IV cocaine, which appears as a rightward and downward shift in the concentration-time profile. Cocaine bioavailability values were similar to previous estimates. Oral cocaine also produced a unique metabolic profile, with greater concentrations of major and minor metabolites.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29462364      PMCID: PMC5952935          DOI: 10.1093/jat/bky007

Source DB:  PubMed          Journal:  J Anal Toxicol        ISSN: 0146-4760            Impact factor:   3.367


  30 in total

1.  Hydrolysis of cocaine in human plasma by cholinesterase.

Authors:  D J Stewart; T Inaba; B K Tang; W Kalow
Journal:  Life Sci       Date:  1977-05-01       Impact factor: 5.037

2.  Butyrylcholinesterase accelerates cocaine metabolism: in vitro and in vivo effects in nonhuman primates and humans.

Authors:  G N Carmona; R A Jufer; S R Goldberg; D A Gorelick; N H Greig; Q S Yu; E J Cone; C W Schindler
Journal:  Drug Metab Dispos       Date:  2000-03       Impact factor: 3.922

3.  Stability of cocaine in biological fluids.

Authors:  R C Baselt
Journal:  J Chromatogr       Date:  1983-10-07

Review 4.  Mechanisms of cocaine hydrolysis and metabolism in vitro and in vivo: a clarification.

Authors:  A Warner; A B Norman
Journal:  Ther Drug Monit       Date:  2000-06       Impact factor: 3.681

5.  Cocaine plasma concentration: relation to physiological and subjective effects in humans.

Authors:  J I Javaid; M W Fischman; C R Schuster; H Dekirmenjian; J M Davis
Journal:  Science       Date:  1978-10-13       Impact factor: 47.728

6.  The effect of ethanol on oral cocaine pharmacokinetics reveals an unrecognized class of ethanol-mediated drug interactions.

Authors:  Robert B Parker; S Casey Laizure
Journal:  Drug Metab Dispos       Date:  2009-11-17       Impact factor: 3.922

7.  Repeated dosing with oral cocaine in humans: assessment of direct effects, withdrawal, and pharmacokinetics.

Authors:  Sharon L Walsh; William W Stoops; David E Moody; Shen-Nan Lin; George E Bigelow
Journal:  Exp Clin Psychopharmacol       Date:  2009-08       Impact factor: 3.157

8.  Formation of p-hydroxycocaine from cocaine by hepatic microsomes of animals and its pharmacological effects in mice.

Authors:  K Watanabe; Y Hida; T Matsunaga; I Yamamoto; H Yoshimura
Journal:  Biol Pharm Bull       Date:  1993-10       Impact factor: 2.233

9.  Purification and characterization of a human liver cocaine carboxylesterase that catalyzes the production of benzoylecgonine and the formation of cocaethylene from alcohol and cocaine.

Authors:  M R Brzezinski; T L Abraham; C L Stone; R A Dean; W F Bosron
Journal:  Biochem Pharmacol       Date:  1994-11-01       Impact factor: 5.858

10.  Kinetics of cocaine distribution, elimination, and chronotropic effects.

Authors:  M J Chow; J J Ambre; T I Ruo; A J Atkinson; D J Bowsher; M W Fischman
Journal:  Clin Pharmacol Ther       Date:  1985-09       Impact factor: 6.875

View more
  6 in total

1.  Cocaine-Induced Ventilation/Perfusion Mismatch Mimicking Pulmonary Embolism.

Authors:  Phani Keerthi Surapaneni; Temidayo Abe; Norberto Fas
Journal:  J Investig Med High Impact Case Rep       Date:  2020 Jan-Dec

Review 2.  Understanding the genetics and neurobiological pathways behind addiction (Review).

Authors:  Alexandra Popescu; Maria Marian; Ana Miruna Drăgoi; Radu-Virgil Costea
Journal:  Exp Ther Med       Date:  2021-03-23       Impact factor: 2.447

3.  Prevalence and associated factors of sexually transmitted infections among methamphetamine users in Eastern China: a cross-sectional study.

Authors:  Xing Ye; Fu-Rong Li; Qing Pan; Zhen Li; Gong-Qi Yu; Hong Liu; Jian Liu; Peng-Cheng Huai; Fu-Ren Zhang
Journal:  BMC Infect Dis       Date:  2022-01-04       Impact factor: 3.090

4.  Age of Onset and Its Related Factors in Cocaine or Methamphetamine Use in Adults from the United States: Results from NHANES 2005-2018.

Authors:  Alexandre Arthur Guerin; Jee Hyun Kim
Journal:  Int J Environ Res Public Health       Date:  2021-11-22       Impact factor: 3.390

Review 5.  Beauty of the beast: anticholinergic tropane alkaloids in therapeutics.

Authors:  Kyu Hwan Shim; Min Ju Kang; Niti Sharma; Seong Soo A An
Journal:  Nat Prod Bioprospect       Date:  2022-09-16

6.  Positivity to Cocaine and/or Benzoylecgonine in Confirmation Analyses for On-Road Tests in Spain.

Authors:  Francisco Herrera-Gómez; Eduardo Gutiérrez-Abejón; Mercedes García-Mingo; F Javier Álvarez
Journal:  Int J Environ Res Public Health       Date:  2021-05-18       Impact factor: 3.390

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.